Pharma: Clinic Roundup
Thursday, July 26, 2012
Sanofi Pasteur, the vaccines division of Paris-based Sanofi SA, said its tetravalent dengue vaccine candidate demonstrated proof of efficacy against dengue, generating antibody response for all four dengue virus serotypes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.